Document Detail

Using pegylated interferon alfa-2b and ribavirin to treat chronic hepatitis patients infected with hepatitis c virus genotype 1: are nonresponders and relapsers different populations?
MedLine Citation:
PMID:  18327466     Owner:  NLM     Status:  MEDLINE    
The combination of pegylated interferon (PEG-INF) and ribavirin is currently the best treatment for chronic hepatitis C, providing a sustained virological response (SVR) in 54%-63% of patients. In patients infected with hepatitis C virus (HCV) genotype 1, the SVR rate is 42%-52%. To evaluate the treatment efficacy of this drug combination, we conducted an open, prospective study of 58 consecutive treatment-naïve patients infected with HCV genotype 1 and treated at a university hospital, comparing those presenting an SVR (SVRs), nonresponders (NRs), and relapsers (RELs). Among the intent-to-treat patients, an end-of-treatment virological response was achieved in 69% of the sample as a whole and in 52% of the SVRs. We found that being an SVR was significantly associated with mild fibrosis (p = 0.04) and with undetectable HCV RNA at weeks 12 and 24 of treatment (p < 0.0001). Comparing the SVR and REL groups, we observed that being older than 40 was significantly associated with being a REL (p = 0.04). Being an NR was found to be associated with severe fibrosis and moderate inflammatory infiltrates (portal or periportal). In the polytomous logistic regression, no independent factors were associated with the REL group when compared with the SVR group. We conclude that RELs and NRs differ in comparison with SVRs. The RELs accounted for 17% of the sample. The HCV RNA test results at weeks 12 and 24 of treatment, although independent predictors of non-response (OR: 4.8 and 8.2, respectively), did not differ between SVRs and RELs.
Giovanni Faria Silva; Rodrigo José Polônio; Maria Inês Moura Campos Pardini; Silvia Maria Corvino; Rita Maria Saccomano Henriques; Mari Nilce Peres; Liciana Vaz Arruda Silveira; Kunie Iabuki Rabello Coelho
Related Documents :
10563526 - Current and evolving therapies for hepatitis c.
17697016 - Risk factors for anaemia in human immunodeficiency virus/hepatitis c virus-coinfected p...
18572756 - Low response to pegylated interferon plus ribavirin in hiv-infected patients with chron...
25348906 - Expression of soluble triggering receptor expressed on myeloid cells-1 in childhood cf ...
23794356 - Albendazole-induced toxic hepatitis: a case report.
21943026 - Hiv surveillance in a large, community-based study: results from the pilot study of pro...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases     Volume:  11     ISSN:  1413-8670     ISO Abbreviation:  Braz J Infect Dis     Publication Date:  2007 Dec 
Date Detail:
Created Date:  2008-03-10     Completed Date:  2008-06-10     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  9812937     Medline TA:  Braz J Infect Dis     Country:  Brazil    
Other Details:
Languages:  eng     Pagination:  554-60     Citation Subset:  IM    
Department of Internal Medicine, Faculdade de Medicina de Botucatu, Botucatu, SP Brazil.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antiviral Agents / therapeutic use*
Drug Therapy, Combination
Hepacivirus / genetics
Hepatitis C, Chronic / drug therapy*,  virology
Interferon Alfa-2b / therapeutic use*
Middle Aged
Polyethylene Glycols
Prospective Studies
RNA, Viral
Ribavirin / therapeutic use*
Treatment Outcome
Reg. No./Substance:
0/Antiviral Agents; 0/Polyethylene Glycols; 0/RNA, Viral; 0/peginterferon alfa-2b; 36791-04-5/Ribavirin; 99210-65-8/Interferon Alfa-2b

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Induced sputum versus bronchoalveolar lavage in the diagnosis of pneumocystis jiroveci pneumonia in ...
Next Document:  Assessing risk behaviors and prevalence of sexually transmitted and blood-borne infections among fem...